In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s shares closed today at $23.87.
Nadeau covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Biogen, and BioMarin Pharmaceutical. According to TipRanks, Nadeau has an average return of 5.5% and a 45.02% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Enliven Therapeutics with a $35.50 average price target.
Based on Enliven Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $20.77 million. In comparison, last year the company had a GAAP net loss of $10.55 million
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ELVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enliven Therapeutics (ELVN) Company Description:
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
Read More on ELVN:
- Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
- Enliven files to sell 6.43M shares of common stock for holders
- Short Report: Bears reduce exposure to Kohlâs as stock momentum fizzles
- Enliven announces proof of concept data from Phase 1 trial of ELVN-001
- Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
